Cantor Fitzgerald Initiates Coverage On Spero Therapeutics with Overweight Rating, Announces Price Target of $6

Benzinga · 3d ago
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Overweight rating and announces Price Target of $6.